Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Awareness, Knowledge, and Treatment Patterns of Nonmetastatic Inflammatory Breast Cancer in Low- and Middle-Income Countries: The BRIDGES Study.
Schlam I, Hirko KA, Shveid D, Abuali I, Sewaralthahab S, Nakhils F, Hazra A, Lengyel C, Altuna S, Hussain S, Seid F, Jamil S, Odhiambo A, Leone JP, Metzger O, Abraham J, Soto-Perez-de-Celis E, Chen WY, Block C, Schumer S, Bellon JR, Valenza C, Curigliano G, Tolaney SM, Lynce F, Trapani D. Schlam I, et al. Among authors: metzger o. JCO Glob Oncol. 2024 Dec;10:e2400307. doi: 10.1200/GO-24-00307. Epub 2024 Dec 20. JCO Glob Oncol. 2024. PMID: 39705637
Implementation of a remote symptom monitoring pathway in oncology care: analysis of real-world experience across 33 cancer centres in France and Belgium.
Franzoi MA, Ferreira AR, Lemaire A, Rodriguez J, Grosjean J, Ribeiro JM, Polastro L, Grellety T, Artignan X, Le Du K, Pagliuca M, Nouhaud É, Autheman M, André F, Basch E, Metzger O, Ferté C, Di Palma M, Scotté F, Vaz-Luis I. Franzoi MA, et al. Among authors: metzger o. Lancet Reg Health Eur. 2024 Jul 31;44:101005. doi: 10.1016/j.lanepe.2024.101005. eCollection 2024 Sep. Lancet Reg Health Eur. 2024. PMID: 39444707 Free PMC article.
International survey on invasive lobular breast cancer identifies priority research questions.
Oesterreich S, Pate L, Lee AV, Chen F, Jankowitz RC, Mukhtar R, Metzger O, Sikora MJ, Li CI, Sotiriou C, Shah OS, Koorman T, Ulaner G, Reis-Filho JS, Davidson NM, Van Baelen K, Hutcheson L, Freeney S, Migyanka F, Turner C, Derksen P, Bear T, Desmedt C. Oesterreich S, et al. Among authors: metzger o. NPJ Breast Cancer. 2024 Jul 20;10(1):61. doi: 10.1038/s41523-024-00661-3. NPJ Breast Cancer. 2024. PMID: 39033157 Free PMC article.
Phase Ib dose-escalation trial of taselisib (GDC-0032) in combination with HER2-directed therapies in patients with advanced HER2+ breast cancer.
Grinshpun A, Ren S, Graham N, DeMeo MK, Wrabel E, Carter J, Tayob N, Pereslete A, Hamilton E, Juric D, Mayer EL, Tolaney SM, Krop IE, Metzger O. Grinshpun A, et al. Among authors: metzger o. ESMO Open. 2024 Jun;9(6):103465. doi: 10.1016/j.esmoop.2024.103465. Epub 2024 Jun 3. ESMO Open. 2024. PMID: 38833970 Free PMC article. Clinical Trial.
Qualification of a multiplexed tissue imaging assay and detection of novel patterns of HER2 heterogeneity in breast cancer.
Guerriero JL, Lin JR, Pastorello RG, Du Z, Chen YA, Townsend MG, Shimada K, Hughes ME, Ren S, Tayob N, Zheng K, Mei S, Patterson A, Taneja KL, Metzger O, Tolaney SM, Lin NU, Dillon DA, Schnitt SJ, Sorger PK, Mittendorf EA, Santagata S. Guerriero JL, et al. Among authors: metzger o. NPJ Breast Cancer. 2024 Jan 2;10(1):2. doi: 10.1038/s41523-023-00605-3. NPJ Breast Cancer. 2024. PMID: 38167908 Free PMC article.
Survival Outcomes in Premenopausal Patients With Invasive Lobular Carcinoma.
Yoon TI, Jeong J, Lee S, Ryu JM, Lee YJ, Lee JY, Hwang KT, Kim H, Kim S, Lee SB, Ko BS, Lee JW, Son BH, Metzger O, Kim HJ. Yoon TI, et al. Among authors: metzger o. JAMA Netw Open. 2023 Nov 1;6(11):e2342270. doi: 10.1001/jamanetworkopen.2023.42270. JAMA Netw Open. 2023. PMID: 37938845 Free PMC article.
Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor-Positive Breast Cancer.
Hermida-Prado F, Xie Y, Sherman S, Nagy Z, Russo D, Akhshi T, Chu Z, Feit A, Campisi M, Chen M, Nardone A, Guarducci C, Lim K, Font-Tello A, Lee I, García-Pedrero J, Cañadas I, Agudo J, Huang Y, Sella T, Jin Q, Tayob N, Mittendorf EA, Tolaney SM, Qiu X, Long H, Symmans WF, Lin JR, Santagata S, Bedrosian I, Yardley DA, Mayer IA, Richardson ET, Oliveira G, Wu CJ, Schuster EF, Dowsett M, Welm AL, Barbie D, Metzger O, Jeselsohn R. Hermida-Prado F, et al. Among authors: metzger o. Cancer Res. 2023 Oct 2;83(19):3284-3304. doi: 10.1158/0008-5472.CAN-23-1711. Cancer Res. 2023. PMID: 37450351 Free PMC article.
Assessment of the HER2DX Assay in Patients With ERBB2-Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab.
Waks AG, Ogayo ER, Paré L, Marín-Aguilera M, Brasó-Maristany F, Galván P, Castillo O, Martínez-Sáez O, Vivancos A, Villagrasa P, Villacampa G, Tarantino P, Desai N, Guerriero J, Metzger O, Tung NM, Krop IE, Parker JS, Perou CM, Prat A, Winer EP, Tolaney SM, Mittendorf EA. Waks AG, et al. Among authors: metzger o. JAMA Oncol. 2023 Jun 1;9(6):835-840. doi: 10.1001/jamaoncol.2023.0181. JAMA Oncol. 2023. PMID: 37103927 Free PMC article.
55 results